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A  retrospective  analysis  of data  from  patients  receiving  daptomycin  as  outpatient  parenteral  antimicro-
bial  therapy  (OPAT)  within  the  European  Cubicin  Outcomes  Registry  and  Experience  (EU-CORESM) was
performed.  Of  4592  enrolled  patients  in  15  countries,  550 (12%)  received  daptomycin  OPAT.  Of  these,  149
(27%) received  daptomycin  without  hospital  admission,  84%  had  signiﬁcant  underlying  diseases  and  44%
were  ≥65  years  of age.  Most  frequently  treated  infections  were  complicated  skin  and  soft-tissue  infections
(28%),  osteomyelitis  (17%),  foreign  body/prosthetic  infections  (15%)  and  endocarditis  (14%).  In  patients
with  culture  results  available,  Staphylococcus  aureus  and coagulase-negative  staphylococci  were  the most
commonly  isolated  primary  pathogens  [n  =  218  (46%)  and  n =  102  (21%),  respectively].  Daptomycin  was
typically  used  at  doses  of 6  mg/kg  (n = 210;  38%)  and  4 mg/kg  (n  =  160;  29%),  with  concomitant  antibiotics
used  in  41%.  The  median  treatment  duration  was  22  days  (range  1–300  days),  with  a median  of  13 OPAT
days  (range  1–290  days).  Overall  clinical  success  was  observed  in  89%,  with  high  success  rates  across
the  wide  range  of  infections,  including  those  caused  by  meticillin-resistant  and  meticillin-susceptible  S.
aureus  (88%  and  90%,  respectively).  Daptomycin  exhibited  a favourable  safety  proﬁle;  3.1%  of  patients
discontinued  treatment  owing  to  an  adverse  event.  These  data  demonstrate  that  daptomycin  is  effective
and well  tolerated  in  the  treatment  of  a  wide  range  of  Gram-positive  infections  in  the  outpatient  setting.
Ease  of administration  of  daptomycin,  via  a daily  2-min  injection,  and  its efﬁcacy  and  safety  combine  to
make  it  an  attractive  treatment  option  for OPAT.. Introduction
Outpatient parenteral antimicrobial therapy (OPAT) is a well-
stablished strategy to treat a wide range of infections, including
kin and soft-tissue infections (SSTIs), bacteraemia, osteomyelitis
nd infective endocarditis (IE), in many parts of the world and
ncreasingly in Europe [1,2]. Administration of intravenous antibac-
erial therapy in an outpatient setting reduces the length of hospital
tay, thereby reducing hospitalisation costs, improving quality of
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life for patients and potentially reducing the risk of healthcare-
associated infection [3–5].
Daptomycin (Cubicin®; Novartis Pharma AG, Basel, Switzerland)
is a bactericidal lipopeptide antibiotic with proven efﬁcacy against
Gram-positive pathogens [6,7], currently licensed for the treatment
of complicated SSTIs (cSSTIs), right-sided IE due to Staphylococcus
aureus, and S. aureus bacteraemia when associated with right-sided
IE or cSSTI [8].  It has several properties that make it an attractive
agent for OPAT: its half-life of 7–9 h supports once-daily dosing, it
does not require therapeutic drug monitoring [8] and it has a short
(2-min) administration time.
Open access under CC BY-NC-ND license. The European Cubicin Outcomes Registry and Experience (EU-
CORESM) is a non-interventional, retrospective patient registry
evaluating the real-world usage of daptomycin for Gram-positive
infections in clinical practice. The primary objectives of EU-CORE
ccess under CC BY-NC-ND license. 
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Table 1
Baseline patient characteristics (N = 550).
Characteristic Patients [n (%)]a
Gender
Female 207 (38)
Male 343 (62)
Age  (years) (mean ± S.D.) 59 ± 18
Age group
<65 years 308 (56)
≥65  years (including ≥75 years) 242 (44)
≥75  years 107 (19)
Body weight (kg) (mean ± S.D.) 76.0 ± 19
Race, Caucasian 465 (85)
Neutropenia at baseline or during daptomycin therapy 31 (6)
Renal function
CLCr < 30 mL/min 50 (9)
Receiving dialysis 26 (5)
Frequent signiﬁcant underlying disease (>7%)b
Hypertension 134 (24)
Diabetes mellitus 119 (22)
Renal disease 60 (11)
Cancer 59 (11)
Cardiac arrhythmias 58 (11)
Country of treatment
Spain 147 (27)
UK  126 (23)
Italy 125 (23)
Venezuela 55 (10)
France 23 (4)
Argentina 22 (4)
Germany 9 (2)
Brazil 8 (1)
Slovenia 8 (1)
Austria 6 (1)
Greece 6 (1)
Columbia 5 (1)
India 5 (1)
Mexico 4 (1)
Turkey 1 (0.2)
S.D., standard deviation; CLCr, creatinine clearance.R.A. Seaton et al. / International Journa
re to characterise the prescribing patterns and to evaluate clinical
utcomes and adverse events (AEs) associated with the use of dap-
omycin. This report describes the data collected from patients in
U-CORE receiving OPAT daptomycin.
. Methods and materials
.1. Patients and data collection
This analysis includes all patients enrolled in EU-CORE who
eceived at least one dose of daptomycin without overnight hos-
italisation, with treatment initiated and completed between 19
anuary 2006 and 30 June 2011. Patients who received treatment
ither partly in the outpatient setting or exclusively in the commu-
ity setting were included.
The EU-CORE methodology has been described previously [9].
nvestigators were asked to enrol patients who qualiﬁed by: being
reated with at least one dose of daptomycin; having a follow-up
f ≥30 days after the end of treatment; and having access to all
linical information requested in the case report forms. Patients
ho had received daptomycin in controlled clinical trials were
xcluded. Written informed consent that complies with the Inter-
ational Conference on Harmonisation of Good Clinical Practice
uideline was  obtained by the Institutional Review Board or Ethics
ommittee and/or local data privacy regulations, as required, and
he protocol was approved by the Health Authority and the Insti-
utional Review Board or Ethics Committee, if applicable, in each
ountry.
Demographic, primary infection, antimicrobial treatment, and
icrobiological and clinical outcomes data were collected using a
tandardised case report form and protocol [9].  AEs and serious AEs
SAEs), regardless of drug relationship (determined by the investi-
ator), were collected during daptomycin treatment and the 30-day
ollow-up period.
.2. Deﬁnitions
Clinical outcomes at the end of daptomycin therapy were
ssessed by investigators using protocol-deﬁned criteria. Cure was
eﬁned as resolution of clinical signs and symptoms and/or no addi-
ional antibiotic therapy necessary, or negative culture reported at
he end of therapy; improved, as partial resolution of clinical signs
nd symptoms and/or additional antibiotic therapy warranted at
he end of therapy; failure, as inadequate response to therapy,
orsening or new/recurrent signs and symptoms, need for a change
n antibiotic therapy, or positive culture reported at the end of ther-
py; and non-evaluable, as unable to determine response because
f insufﬁcient information [9].  The term clinical success was  used
o describe patients with a cured or improved outcome. Duration of
reatment was the number of days a patient received daptomycin
reatment (even when non-consecutive). The reported daptomycin
ose is the nominal dose per administration regardless of dosing
nterval [e.g. whether a patient received daptomycin once daily as
ecommended for creatinine clearance (CLCr) ≥30 mL/min, or every
8 h as recommended for CLCr < 30 mL/min].
. Results
.1. Patient demographics and clinical characteristics
Of 4592 patients reported, 550 (12%) received daptomycin OPAT
Table 1). The mean age of OPAT patients was 59 years, with 44%
ged ≥65 years at the start of treatment; 463 patients (84%) had
igniﬁcant underlying diseases (Table 1). Concomitant use of statins
ith daptomycin therapy was reported in 64 patients (12%). Beforea Data are n (%) unless otherwise stated.
b Patients may  have one or more underlying diseases; severity of underlying dis-
eases was  not captured in the case report forms.
the start of OPAT, 331 patients (60%) were hospitalised, 34% were in
the community setting and the remainder were in nursing homes,
extended care or other settings.
Diverse types of primary infection were treated with dapto-
mycin OPAT, most commonly cSSTIs (152; 28%). Other infections
treated included osteomyelitis (93; 17%), foreign body/prosthetic
infections (81; 15%), endocarditis (76; 14%), bacteraemia (66; 12%),
uncomplicated SSTIs (uSSTI) (58; 11%) and septic arthritis (12; 2%).
Secondary infections were reported in 76 patients (14%).
3.2. Microbiology
Daptomycin was  used empirically in 207 patients (38%);
microbiological samples were obtained in 476 patients (87%)
(Table 2). Positive culture results were available for 394 patients
(72%). Staphylococcus aureus and coagulase-negative staphylococci
(CoNS) were the most commonly isolated primary pathogens
[n = 218 (46%) and n = 102 (21%), respectively]. Approximately
one-half of the S. aureus isolates were meticillin-resistant, and
Staphylococcus epidermidis was  the most common CoNS pathogen.
Enterococci were also isolated, all of which were susceptible to
vancomycin. Fifty-eight patients (11%) had cultures positive for
secondary pathogens.3.3. Previous and concomitant antibiotic treatment
Prior antibiotic therapy was  recorded in 431 patients (78%). Gly-
copeptides and penicillins were the most commonly prescribed
470 R.A. Seaton et al. / International Journal of An
Table  2
Culture results of microbiological samples (N = 476).
Primary pathogen isolated Patients [n (%)]
Staphylococcus aureus 218 (46)
MSSA 93 (20)
MRSA 114 (24)
Meticillin susceptibility unknown 11 (2)
CoNS 102 (21)
Staphylococcus epidermidis 60 (13)
Other CoNS 42 (9)
Enterococcus faecalis 20 (4)
Enterococcus faecium 7 (1)
Othera 47 (10)
Culture negative 82 (17)
MSSA, meticillin-susceptible S. aureus; MRSA, meticillin-resistant S. aureus; CoNS,
coagulase-negative staphylococci.
a Other pathogens include Staphylococcus spp. coagulase not speciﬁed, Enterococ-
cus spp., Streptococcus agalactiae or Group B streptococci, Streptococcus pyogenes
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ositive cocci, Gram-negative bacilli, Corynebacterium spp., Clostridium perfringens,
ungi/yeast and Gram-positive bacilli.
lasses of antibiotics before daptomycin therapy, in 179 patients
33%) and 174 patients (32%), respectively; vancomycin was the
ost frequently used glycopeptide (n = 110; 20%) (note, patients
ould have received more than one antibiotic before daptomycin).
luoroquinolones (n = 91; 17%), aminoglycosides (n = 88; 16%) and
ephalosporins (n = 81; 15%) were also commonly used. Treatment
ailure was the most common reason for discontinuing prior ther-
py (n = 266; 48%). Other frequent reasons for switching therapy
o daptomycin included narrowing of the antibiotic spectrum in
02 patients (19%) and intolerance/toxicity in 97 patients (18%).
se of antibiotics concomitantly with daptomycin in the outpatient
etting was common (n = 226; 41%), with ﬂuoroquinolones (n = 53;
0%), carbapenems (n = 23; 4%) and cephalosporins (n = 20; 4%) used
ost frequently.
.4. Daptomycin prescribing patterns
The most frequently prescribed doses for daptomycin OPAT
ere 6 mg/kg (n = 210; 38%) and 4 mg/kg (n = 160; 29%); 114
atients (21%) and 57 patients (10%) received >6 mg/kg or >4 mg/kg
nd <6 mg/kg, respectively; only 3 patients (0.5%) received
4 mg/kg (dosing data unavailable for 6 patients). For patients
eceiving daptomycin OPAT for uSSTIs and cSSTIs, a 4 mg/kg dose
as most frequently used (71% and 57%, respectively), whereas
 dose of 6 mg/kg was used most often to treat bacteraemia
71%), foreign body/prosthetic infections (49%), endocarditis (47%)
nd osteomyelitis (47%). Doses >6 mg/kg were most common for
steomyelitis (43%), endocarditis (37%), septic arthritis (33%) and
oreign body/prosthetic infections (30%).
The median total duration of daptomycin OPAT was  22 days
range 1–300 days), with a median 10 days (1–183 days) inpatient
nd 13 days (1–290 days) outpatient treatment; 149 patients (27%)
eceived daptomycin as outpatient treatment only. The median
uration of outpatient treatment for uSSTIs, cSSTIs and bacteraemia
as 7 days (1–28 days), 10 days (1–189 days) and 12 days (2–83
ays), respectively. For endocarditis, foreign body/prosthetic infec-
ion and osteomyelitis, the mean duration was 21 days (5–85 days),
3 days (2–290 days) and 28 days (2–89 days), respectively.
.5. Clinical outcome
Clinical success was achieved by 488 patients (89%) receiving
aptomycin OPAT, with the highest clinical success rates in patients
ith bacteraemia or endocarditis (Fig. 1A). Success rates for these
nfections were similarly high in those aged ≥65 years (97% and
5%, respectively). Treatment failure rates were low (<10%) acrosstimicrobial Agents 41 (2013) 468– 472
all types of infection. High rates of clinical success were also
observed across the different primary pathogens (Fig. 1B).
3.6. Safety
AEs regardless of study drug relationship were reported for
80 patients (15%) receiving daptomycin OPAT; 86% were mild or
moderate in severity. System organ class AEs with an incidence
in patients of ≥2% were: general disorder and administration-site
conditions (14; 2.5%); laboratory investigations (13; 2.4%); and
infections and infestations (12; 2.2%). The most commonly reported
AEs by preferred term were blood creatine phosphokinase (CPK)
increase (8; 1.5%), asthenia (7; 1.3%) and diarrhoea (5; 0.9%). A
total of 17 patients (3.1%) discontinued study drug because of AEs,
including 2 patients (0.4%) with blood CPK elevations and both
patients with rhabdomyolysis. At baseline, two  patients (0.4%) had
CPK levels >10× upper level of normal (ULN); however, during
therapy, nine patients (1.6%) had a maximum CPK >10× ULN. AEs
possibly related to daptomycin were reported for 47 patients (9%).
SAEs were reported in 17 patients (3.1%), of which blood potas-
sium increase in 1 patient, blood CPK increase in 1 patient, vaginal
haemorrhage in 1 patient and rhabdomyolysis in 2 patients were
suspected to be related to study drug. One patient with sus-
pected rhabdomyolysis was treated with daptomycin 6 mg/kg daily
despite severe renal impairment (CLCr < 30 mL/min). Furthermore,
in this patient, elevated CPK values (>2–5× ULN) were already
reported at baseline. In both patients, rhabdomyolysis completely
resolved after termination of daptomycin. There were two  fatal
cases in the study (pneumonia and device-related infection); nei-
ther was considered to be related to daptomycin.
The number and types of all-cause AEs and SAEs in the ≥65 years
age group were similar to those for the overall treatment popula-
tion: AEs were reported in 34 patients (14%) and SAEs in 14 patients
(5.8%).
Of 443 patients with CLCr measurements at the initiation and
end of daptomycin therapy, 420 (95%) remained in the same or
a higher clearance group; only 4 patients’ measurements fell to
<30 mL/min.
4. Discussion
These data from the EU-CORE analysis over a 5.5-year reporting
period demonstrate that daptomycin has been used successfully
in the outpatient setting for the treatment of a wide range of
Gram-positive infections. Expanding on the results from ran-
domised clinical trials and analysis of data from the ﬁrst 2.5
years of EU-CORE [6,7,10], the data demonstrate that dapto-
mycin has a favourable efﬁcacy, safety and tolerability proﬁle
in the OPAT setting. Although cSSTIs were the most commonly
treated infection type, 62% of patients received daptomycin OPAT
for more complex infection types. Use of daptomycin OPAT for
severe and deep-seated infections such as osteomyelitis and for-
eign body/prosthetic infections—indications for which daptomycin
does not have licensing approval—suggests a lack of appropriate or
convenient alternative antimicrobial options for these infections in
this setting. Daptomycin may  have speciﬁc relevance in this context
owing to its suggested activity in bioﬁlms [11].
The high rates of clinical success observed, ranging from 85%
to 96% for different infection types, may  reﬂect patient selection:
most patients had received prior hospital-based antibiotic ther-
apy, which is likely to have been associated with a therapeutic
improvement before hospital discharge. This may also be supported
by the smaller proportion (41%) of OPAT-treated patients who
received concomitant antibiotic therapy compared with the over-
all EU-CORE population (65%) [9].  Careful patient assessment and
R.A. Seaton et al. / International Journal of Antimicrobial Agents 41 (2013) 468– 472 471
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Fig. 1. Clinical outcomes of outpatient parenteral antibiotic therapy with daptomycin by (A) infection type and (B) primary pathogen (N = 347). Success was the sum of cure
and  improved. Cure rates: (A) All, 45.8%; complicated skin and soft-tissue infections (cSSTIs), 40.1%; bacteraemia, 69.7%; endocarditis, 57.9%; osteomyelitis, 32.3%; foreign
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tody/prosthetic infections, 42.0%; uncomplicated skin and soft-tissue infections (u
ureus  (MSSA), 48.4%; meticillin-resistant S. aureus (MRSA), 49.1%; Staphylococcus
aecalis,  55.0%; Enterococcus faecium, 57.1%. * Other infections include urinary tract 
election is a key requirement within recently published OPAT good
ractice recommendations [4].  Similarly, high rates of success were
eported in patients receiving OPAT who had complicated S. aureus
acteraemia (compared with those treated entirely as inpatients)
n a previously published randomised comparison of daptomycin
ith vancomycin or semisynthetic penicillins [12]. Although it is
ikely that infections treated with daptomycin OPAT within EU-
ORE were likely to be milder than those treated exclusively as
npatients, more than one-half of OPAT patients received doses
f ≥6 mg/kg, reﬂecting the serious nature of their infections. In
ddition, a high proportion of those receiving OPAT were elderly
ith co-morbidities, demonstrating the utility of daptomycin in
his patient population.
It was not possible to determine what proportion of patientswitched to daptomycin primarily to allow OPAT. Conceivably,
ome patients who had achieved a therapeutic response to an
ntibiotic that required multiple daily dosing in the hospital transi-
ioned to daptomycin for daily outpatient administration. Multiple, 46.6%; other, 54.2%. (B) All Staphylococcus aureus,  47.2%; meticillin-susceptible S.
rmidis, 51.7%; other coagulase-negative staphylococci (CoNS), 47.6%; Enterococcus
ions, septic arthritis and central nervous system infections.
daily dosing with ﬂucloxacillin has been reported to be associated
with an increase in line-related complications compared with daily
administered antibiotics in the OPAT setting [13].
Notably, one-third of patients received daptomycin OPAT with-
out prior hospitalisation. This particular group of patients has not
been further characterised but may  reﬂect an increasing trend for
selected patients with SSTIs to be treated exclusively in the OPAT
setting. In this study, daptomycin OPAT was used to treat 152
patients with cSSTIs. In some countries, second- or third-generation
cephalosporins are established therapy choices for the treatment
of SSTIs in the outpatient setting, except when meticillin-resistant
S. aureus infection is suspected, patients are -lactam allergic, or
cephalosporin restrictions are in place because of potential Clostrid-
ium difﬁcile risk. The established European alternative teicoplanin
has recently been associated with a comparatively increased dura-
tion of therapy and higher rate of OPAT failure compared with
ceftriaxone, suggesting the need to consider alternatives, including
daptomycin [14].
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A patient registry has intrinsic limitations, including the non-
omparative, retrospective, non-randomised, unblinded design
nd the subjective nature of investigator assessments and patient
nclusion. As such, and in line with everyday clinical practice, inter-
retation of the clinical outcomes is confounded by the frequent use
f prior and concomitant antibiotics. Also, as there was  no com-
arator group, a formal economic analysis could not be performed.
t is, however, assumed that as hospitalisation is the main driver for
otal healthcare costs, avoidance of admission or reduced hospital
tay facilitated by daptomycin OPAT has economic beneﬁts [4,15].
These results reﬂect real-world experience with daptomycin
PAT in clinical practice and demonstrate its efﬁcacy and tolerabil-
ty for a wide range of Gram-positive, difﬁcult-to-treat infections
n the outpatient setting. The data support the use of daptomycin
ithin the framework of OPAT good practice recommendations
4], making it an attractive option and a potentially economical
lternative to hospitalisation in selected patients.
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